VistaGen Therapeutics News

VistaGen Therapeutics | DEF 14A: Definitive information statements

Apr 16 06:05 ET

VistaGen Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Apr 5 17:34 ET

VistaGen Therapeutics | 8-K: Current report

Apr 1 17:29 ET

VistaGen Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Rotunno Mary L.

Mar 6 18:05 ET

VistaGen Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director GIN JERRY B

Mar 6 18:05 ET

VistaGen Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director FitzPatrick Margaret M

Mar 6 18:05 ET

VistaGen Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Curley Joanne

Mar 6 18:05 ET

VistaGen Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Cunningham Ann Michelle

Mar 6 18:05 ET

VistaGen Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director SAXE JON S

Mar 6 18:05 ET

VistaGen Therapeutics | EFFECT: Others

Mar 1 06:09 ET

VistaGen Therapeutics | CORRESP: CORRESP

Feb 27 13:40 ET

VistaGen Therapeutics | UPLOAD: Others

Feb 16 13:40 ET

VistaGen Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Kenneth Griffin(5.8%),Citadel Advisors LLC(5.6%), etc.

Feb 14 18:23 ET

VistaGen Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Nantahala Capital Management, LLC(9.9%),Wilmot B. Harkey(9.9%), etc.

Feb 14 16:58 ET

VistaGen Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Great Point Partners, LLC(9.99%),Dr. Jeffrey R. Jay, M.D.(9.99%), etc.

Feb 14 16:46 ET

VistaGen Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Point72 Asset Management, L.P.(3.0%),Point72 Capital Advisors, Inc.(3.0%), etc.

Feb 14 08:57 ET

VistaGen Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-The Vanguard Group(6.79%)

Feb 13 22:30 ET

VistaGen Therapeutics | S-3: Registration statement for specified transactions by certain issuers

Feb 13 16:57 ET

VistaGen Therapeutics | 8-K: Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update

Feb 13 16:35 ET

VistaGen Therapeutics | 10-Q: Quarterly report

Feb 13 16:31 ET